Valinor Drug Patent Portfolio

Valinor owns 1 orange book drug protected by 6 US patents Given below is the list of Valinor's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9012469 Crystalline naloxol-peg conjugate 02 Apr, 2032
Active
US7786133 Chemically modified small molecules 16 Sep, 2028
Active
US8067431 Chemically modified small molecules 16 Dec, 2024
Active
US7056500 Polymer conjugates of opioid antagonists 29 Jun, 2024 Expired
US7662365 Polymer conjugates of opioid antagonists 18 Oct, 2022 Expired
US8617530 Polymer conjugates of opioid antagonists 18 Oct, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Valinor.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 14 Sep, 2022 US9012469
Payment of Maintenance Fee, 12th Year, Large Entity 13 Jan, 2022 US7786133
Patent Term Extension Certificate 06 Dec, 2021 US7786133
Payment of Maintenance Fee, 12th Year, Large Entity 15 Jul, 2021 US7662365
Payment of Maintenance Fee, 8th Year, Large Entity 13 May, 2021 US8617530
Mail Certificate of Correction Memo 06 May, 2021 US9012469
Certificate of Correction Memo 05 May, 2021 US9012469
Post Issue Communication - Certificate of Correction 05 May, 2021 US9012469
Notice of Final Determination -Election Required 16 Feb, 2021 US7786133
Notice of Final Determination -Election Required 16 Feb, 2021 US7662365
Change in Power of Attorney (May Include Associate POA) 08 Jul, 2020 US9012469
Correspondence Address Change 07 Jul, 2020 US9012469
FDA Final Eligibility Letter 07 Mar, 2019 US7786133
FDA Final Eligibility Letter 07 Mar, 2019 US7662365
Payment of Maintenance Fee, 4th Year, Large Entity 13 Sep, 2018 US9012469


Valinor's Drug Patent Litigations

Valinor's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 15, 2015, against patent number US7786133. The petitioner Neptune Generics, LLC, challenged the validity of this patent, with NEKTAR THERAPEUTICS as the respondent. Click below to track the latest information on how companies are challenging Valinor's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7786133 October, 2015 Terminated-Denied
(27 Apr, 2016)
NEKTAR THERAPEUTICS Neptune Generics, LLC


Valinor Drug Patents' Oppositions Filed in EPO

Valinor drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 22, 2014, by Generics (Uk) Ltd (Trading As Mylan). This opposition was filed on patent number EP04814802A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11829686A Sep, 2016 ABG Patentes, S.L. Patent maintained as amended
EP11829686A Sep, 2016 Stada-Arzneimittel Aktiengesellschaft Patent maintained as amended
EP11829686A Sep, 2016 Generics [UK] Limited Patent maintained as amended
EP04814802A Oct, 2014 Generics (UK) Ltd (trading as Mylan) Opposition rejected


Valinor's Family Patents

Valinor drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 18.2% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Valinor Drug List

Given below is the complete list of Valinor's drugs and the patents protecting them.


1. Movantik

Movantik is protected by 6 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9012469 Crystalline naloxol-peg conjugate 02 Apr, 2032
(7 years from now)
Active
US7786133 Chemically modified small molecules 16 Sep, 2028
(3 years from now)
Active
US8067431 Chemically modified small molecules 16 Dec, 2024
(2 months from now)
Active
US7056500 Polymer conjugates of opioid antagonists 29 Jun, 2024
(3 months ago)
Expired
US7662365 Polymer conjugates of opioid antagonists 18 Oct, 2022
(1 year, 11 months ago)
Expired
US8617530 Polymer conjugates of opioid antagonists 18 Oct, 2022
(1 year, 11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Movantik's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List